Highlights:
- First participants enrolled in USU Travelan Clinical Trial Field Study
- 157 participants successfully randomized into the Clinical Study
- Plans in place to enrol in 1302 healthy volunteers in total
- Infectious diarrhea is the most common illness reported by travelers & military personnel
After overcoming significant challenges due to the COVID-19 pandemic and international travel restrictions and COVID-19 related quarantine period enforced by many countries the USU has reported that to date it has successfully recruited 157 participants into the clinical study following the initiation of enrolment (ASX announcement
USU’s Infectious Diseases Clinical Research Program (IDCRP), the
The Problem: Travelers’ diarrhea (TD) remains a highly prevalent disease that impacts operational readiness of military personnel and is also debilitating civilian travel. In addition to its acute morbidity, TD is associated with acquisition of antimicrobial resistance genes and long-term sequelae. Current mitigation strategies including pre-travel counseling and antibiotics for prevention and treatment have important limitations, and there are currently no licensed, pathogen-specific vaccines for TD prevention.
The Approach: Prebiotics, probiotics and passive immunotherapy may offer safe and relatively inexpensive preventive strategies by promoting gut resistance to enteropathogens, and potentially lessening the use of antibiotics. USU’s Infectious Diseases Clinical Research Program (IDCRP), the
This release has been authorised by the directors of
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About
For more information visit: http://www.immuron.com
![](https://ml.globenewswire.com/media/YTUwM2E2ZjMtODQzYi00Y2YwLWJhNmMtZTc2YTU2MDI3NmY0LTEwMzE4NjU=/tiny/Immuron-Limited.png)
2023 GlobeNewswire, Inc., source